Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
Eli Lilly will hike the UK list price of its weight-loss drug Mounjaro by a dramatic 170% starting September, pushing the monthly cost for the highest dose from £122 to £330. The price increase also applies to the drug’s type 2 diabetes indication. This move comes as US policymakers pressure pharma companies to raise European prices, aiming to allow for price reductions in the American market.
The higher price will mainly affect private-pay patients in the UK, while those receiving Mounjaro through the National Health Service (NHS) will not be impacted due to a separate agreement. When Mounjaro was first launched in Britain, Lilly set an intentionally low price to speed up NHS availability. Now, the company says it is "aligning the list price more consistently" with other European nations.
This adjustment highlights the pharmaceutical industry’s response to US efforts to close the gap between American and European drug prices, which can be nearly triple in the US. As pressure mounts from the White House, Lilly’s CEO has indicated that long-term parity in drug pricing across regions is a goal, but warned that European governments are reluctant to pay more.
Lilly is working with private health providers and online pharmacies to ensure patients retain access to Mounjaro despite the sharp price jump. The drug was introduced in the UK in February last year, shortly before Novo Nordisk’s rival weight-loss drug Wegovy entered the same market.
2026-10-14
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Two Major Chemical Companies Collapse in May as the Global Industry Faces a Broad Downturn
-
Akzo Nobel and Axalta Announce a $25 Billion Merger Deal
-
Clariant and FUHUA Establish Joint Venture to Co-Develop Halogen-Free Flame Retardants
-
SABIC Agri-Nutrients Advances Mega Fertilizer Expansion With 1.2 Million MT/Year Ammonia Plant
-
Sinopec Oilfield Service Chairman Steps Down, Sinopec Shanghai Sales Branch Deputy GM Investigated on Consecutive Days
-
BASF Raises Acid Chloride and Chloroformate Capacity by 30% at Ludwigshafen
-
BASF Sues Apple Over Face Authentication Patents Used in Dozens of iPhones and iPads
-
Ineos Rescues UK's Last Dichloroethane Plant
-
Eurofragance Launches Proprietary Fragrance Ingredient Olivante
-
Huntsman Partners with Wobatek to Expand TPU Distribution
Recommend Reading
-
LANXESS Raises Global 1,6-Hexanediol Prices by 20% as Cost Pressure Begins to Pass Downstream
-
BorsodChem Raises MDI Prices by €500 as Cost Pressure in Europe’s Polyurethane Chain Continues to Escalate
-
BASF Raises BA and 2-EHA Prices as Acrylic Ester Costs Continue to Move Higher in Asia-Pacific
-
BASF and Hannong Chemical Joint Venture Nonionic Surfactant Plant Begins Operation in South Korea
-
Wanhua’s Counter-Cyclical Expansion: A Gamble or a Strategic Move for the Next Cycle?
-
EFSA Reviews Clodinafop Risk
-
Cost-Driven Dichloromethane Prices Rise Over 35% in March
-
Domestic SBR Market Shows Strong Unilateral Increase
-
China's Acetic Acid Market Continues to Rise
-
On March 24, China's titanium dioxide market prices increased